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Abstract
Objective: To investigate clinical effectiveness of prednisolone (PSL) and cyclosporin A (CyA), particularly continuous intravenous 
administration of the latter, in patients with interstitial pneumonia (IP) associated with polymyositis/dermatomyositis (PM/DM).
Methods: We reviewed the clinical findings and therapeutic outcomes of patients with PM/DM who had received PSL and CyA 
(PSL + CyA, n = 21 for DM and 2 for PM) or the former alone (n = 12 for DM and 7 for PM). All patients receiving PSL + CyA had 
active IP.
Results: Fifteen of the 21 DM patients receiving PSL + CyA showed favorable therapeutic outcomes of IP (recovery group), while the 
remaining 6 died of respiratory failure (death group). Before treatment PaO2 in room air and %VC were significantly lower, and the 
total CT score was significantly higher in the death group than in the recovery one. Continuous intravenous administration of CyA was 
performed in 6 patients for severe IP requiring oxygen therapy, and of these 2 showed complete recovery from it.
Conclusions: Coadministration of PSL and CyA, particularly continuous intravenous infusion of the latter, from the early phase of 
illness may be a potent therapeutic option for PM/DM patients with decreases in PaO2 and %VC and/or a high total CT score suggestive 
of a poor prognosis.
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Introduction
Polymyositis  (PM)  and  dermatomyositis  (DM) 
are  autoimmune  inflammatory  systemic  disorders 
primarily targeting skeletal muscles with or without 
skin involvement. Several recent reports have dem-
onstrated obvious differences in flow cytometry of 
circulating peripheral blood and immunohistochem-
istry of skeletal muscles between PM and DM,1–3 but 
both  disorders  are  similar  with  regard  to  showing 
an important role of activated T-lymphocytes in the 
pathogenesis.4 To control the disease activity of PM 
and DM via suppression of activated T-lymphocytes, 
calcineurin inhibitors, such as cyclosporin A (CyA) 
and tacrolimus, have recently been used for treatment 
of  refractory  cases  unresponsive  to  corticosteroid 
alone, particularly in patients with progressive inter-
stitial pneumonia (IP) in which many CD8-positive 
cells are frequently detectable in both the alveolar 
wall and bronchoalveolar fluid.5–7 Additional use of 
calcineurin inhibitors in these cases may be able to 
promote early recovery, save life and also reduce cor-
ticosteroid-induced adverse events.1,8–11
In the present study we retrospectively investigated 
the clinical outcomes of prednisolone (PSL) and CyA 
in acute IP complicating PM/DM in order to clarify 
therapeutic efficacy and adverse effects. We postulate 
that additional use of CyA to corticosteroid, particu-
larly  continuous  intravenous  administration  of  the 
former in the early phase of illness, may be a potent 
therapeutic  option  for  PM/DM  patients  associated 
with IP probably showing a poor prognosis.
patients and Methods
Patients
We studied 9 patients with PM (8 women and 1 man; 
mean  age  65  ±  15  years,  range  28  to  81)  and  33 
patients with DM (20 women and 13 men; mean age 
52 ± 17 years, range 15 to 83) who had been admitted 
to our hospital from January 2002 to August 2010. The 
diagnoses of PM and DM were made according to the 
classification criteria proposed by Bohan and Peter.12 
None of the patients had received any treatment prior 
to admission to our hospital, and presented with some 
of  the  clinical  manifestations  and  laboratory  data 
suggestive of active disease, such as muscle weakness, 
skin symptoms and increases in serum creatine kinase 
(CK). Sixteen of the DM patients were compatible 
with  clinically  amyopathic  DM  (CADM)  with 
regard to showing typical skin symptoms, including 
heliotrope rash, Gottron’s sign and ulcerations, with no 
or little muscle involvement.13 No patients had either 
malignancy on intensive systemic survey or obvious 
renal dysfunction on routine laboratory examinations. 
Other clinical information, such as C-reactive protein 
(CRP) and autoantibodies, was obtained from their 
medical  records.  The  Local  Ethical  Committee 
approved this study.
Clinical assessment of IP
We assessed pulmonary involvement in the patients 
using  the  following  indices:  chest  X-ray,  high 
resolution  computed  tomography  (HRCT),  arterial 
oxygen pressure (PaO2) in room air, serum KL-6 and 
respiratory function tests, including a percent vital 
capacity (%VC) and a percent diffusing capacity for 
carbon monoxide (%DLco). HRCT was performed 
using  LightSpeed  VCT  VISION  (GE  Healthcare 
Japan; Hino, Japan), with 2-mm collimation at 15-mm 
intervals at end inspiration from the lung apices to 
the bases. All images were reconstructed with a high-
spatial  frequency  algorithm,  and  photographed  at 
window widths of −1500 H.U. and window levels 
of −600 H.U. To discover interstitial changes in lungs, 
we focus upon the following CT findings:14,15 (1) nodular 
opacities: (2) bronchial dilatation and wall thickening, 
including  consolidation  around  bronchovascular 
bundles:  (3)  reticular  opacities,  including  honey-
comb changes: (5) linear opacities and (6) increased 
lung opacities. When the patients with at least one of 
these CT findings showed clinical symptoms, such as 
non-productive cough and exertional dyspnea, with 
impaired respiratory function, particularly decreases 
in  PaO2 ( ,80  mmHg),%VC  (,80%)  and/or  % 
DLco (,70%), associated IP was regarded as active.   
To  assess  IP,  we  selected  6  transverse  CT  images 
taken at the levels of the upper and lower portions 
each of the aortic arch, the hilus and the lower lobe. 
Two raters blinded to the clinical information (YS and 
MM) evaluated the HRCT images focusing the above-
mentioned 6 CT findings suggestive of IP, and used 
the visual estimation method described by Kinoshita 
et al.14 Each CT slice level was divided into 4 areas 
according to a horizontal and a vertical line drawn 
by a rater, and scored in a semiquatitative manner CyA and PSL in acute IP complicating PM/DM
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Table 1. Comparison of clinical profiles and laboratory data on admission between PSL alone and PSL + CyA.
Treatment Dermatomyositis polymyositis
psL alone psL + cyA psL alone psL + cyA
number of patients 12 (5*) 21 (11*) 7 2
Age of onset (years)
  Mean 61 46 64 66
  SD 16 16 17 7
  vs. PSL alone nS
Male/Female
  number 3/9 10/11 0/7 1/1
  vs. PSL alone nS
Initial dose of PSL (mg/kg/day)
  Mean 0.94 1.00 1.00 1.00
  SD 0.16 0.28 0 0
  vs. PSL alone nS
Clinical symptoms
  Muscle weakness
    number 8 10 7 2
    vs. PSL alone nS
  Arthralgia
    number 1 16 0 0
    vs. PSL alone ,0.0001
  Ulcerative skin lesions
    number 0 12 0 0
    vs. PSL alone 0.0008
Laboratory findings
  WBC (/µL)
    Mean 6235 5228 7363 9830
    SD 1993 1251 2397 2772
    vs. PSL alone nS
  Lymphocytes (/µL)
    Mean 674 796 1666 928
    SD 529 453 748 146
    vs. PSL alone nS
  CK (IU/L)
    Mean 3261 (6360**) 1825 (3703**) 4348 2558
    SD 4616 (4882**) 3513 (4464**) 3124 1190
    vs. PSL alone nS (nS**)
  CrP (mg/dL)
    Mean 0.25 1.54 0.28 1.83
    SD 0.25 2.07 0.26 1.61
    vs. PSL alone 0.006
  Positive for anti-nuclear antibody
    number 7 3 2 1
    vs. PSL alone nS
  Positive for anti-Jo-1 antibody
    number 0 1 0 0
    vs. PSL alone nS
Total CT score
  Mean 0.17 10.75 0.43 10.50
  SD 0.58 6.84 0.79 4.95
  vs. PSL alone ,0.0001
notes: *number of patients with amyopathic dermatomyositis, **Values in patients with non-amyopathic dermatomyositis.
Abbreviations:  CK,  creatine  kinase;  CRP,  C-reactive  protein;  CyA,  cyclosporin  A;  NS,  not  significant;  PSL,  prednisolone;  SD,  standard  deviation;  WBC,  white 
blood cells.Shimojima et al
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Figure 1. The total CT score before and after treatment in the PSL + CyA group.
notes: The recovery group of the DM patients showed a significant decrease in the total CT score 1, 3, 6 and 12 months after starting PSL and CyA com-
pared with before (P , 0.05), while the death group did not. The total CT score in the PM patients also decreased after starting PSL and CyA.
as follows: 0 = absent; 1 = less than 25% involved; 
2  =  25%–50%  involved;  3  =  50%–75%  involved; 
and 4 = greater than 75% involved. The final judgment 
was reached by consensus of the 2 raters. Right and 
left lungs were evaluated separately, and the sum was 
expressed as the total CT score. HRCT was serially 
performed before and after treatment.
Treatment
PSL  was  started  at  a  dose  of  approximately 
1.0 mg/kg/day in all of the patients soon after the 
diagnosis of PM/DM. We added CyA to PSL when 
active IP was evident (PSL + CyA). CyA was orally 
given twice a day initially at a dose of 75 mg, which 
was later controlled to keep the trough concentration 
between 100 and 150 ng/mL. Continuous intravenous 
administration  of  CyA  was  performed  when  oral 
intake of it was difficult because of critical care for 
respiratory failure, such as oxygen therapy with or 
without  mechanical  ventilatory  support.  CyA  was 
started at 0.17 mg/kg/hr, the blood concentration was 
checked at least twice a day, and in order to keep it 
at 250–350 ng/mL the administration speed of CyA 
was controlled. The dose of CyA was reduced at the 
development of renal dysfunction.
Statistics
To determine statistical differences between PSL alone 
and PSL + CyA in PM/DM and also those between 
recovery and death groups in DM, Mann-Whitney’s U 
and Chi-square for independence tests were employed. 
Wilcoxon’s  signed  rank  test  was  used  for  evaluat-
ing alterations of the total CT score. The results were 
expressed as mean ± standard deviation, and a P-value 
less than 0.05 was regarded as statistically significant. 
Commercially available statistics software was used 
for  data  analysis  (StatView  for  Macintosh, Abacus 
Concepts, Berkeley, CA, USA and Excel for   Windows, 
Microsoft, Redmond, WA, USA).
Results
Clinical profiles and laboratory  
findings before treatment
CyA was added to PSL (PSL + CyA) in 21 patients 
with DM, including 11 with CADM, and 2 with PM, CyA and PSL in acute IP complicating PM/DM
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all of whom showed active IP on or after admission. 
Possibilities of infection were excluded on the basis 
of  blood  examinations,  including  serum  antibodies 
to infectious agents, and analyses of bronchoalveolar 
lavage  fluid  in  all  of  these  patients.  Twelve  DM 
patients, including 5 with CADM, and 7 with PM were 
treated only with PSL (PSL alone). Among them 1 DM 
and 2 PM patients revealed mild consolidation around 
bronchovascular bundles and/or honey-comb changes 
on CT, which were regarded as old and inactive IP 
based on  the lack of clinical  symptoms  with  well-
preserved respiratory function. Comparison of clinical 
profiles  and  laboratory  data  on  admission  between 
PSL alone and PSL + CyA is shown in Table 1. There 
was  no  significant  difference  in  the  initial  dose  of 
PSL between PSL alone and PSL + CyA. Among the 
clinical symptoms of DM, arthralgia and ulcerative 
skin lesions were significantly more frequent in PSL 
+ CyA (P , 0.0001 and P , 0.001, respectively) than 
in PSL alone. No significant difference was seen in 
laboratory data between the 2 groups except for CRP in 
the DM patients, which showed a significantly higher 
value in PSL + CyA than in PSL alone (P , 0.01). The 
total CT score in DM showed a significantly higher 
level in PSL + CyA than in PSL alone (P , 0.0001).
Therapeutic outcomes
Fifteen of the 21 DM patients receiving PSL + CyA 
(recovery  group)  showed  favorable  therapeutic 
outcomes of IP, including complete recovery, and no 
serious adverse events except for mild pneumocystis 
pneumonia in 2. The remaining 6 patients receiving 
PSL + CyA (death group) died of respiratory failure 
due  to  active  IP  despite  methylprednisolone  pulse 
Table 2. Comparison of clinical profiles and laboratory data 
on adding CyA between the recovery and death groups of 
DM patients treated with PSL and CyA.
Recovery 
group
Death 
group
number of patients 15 6
Age (years)
  Mean 44 56
  SD 17 10
  vs. recovery group nS
Amyopathic type
  number 8 3
  vs. recovery group nS
Male/ Females 7/8 4/2
  number
  vs. recovery group nS
Initial dose of PSL (mg/kg/day)
  Mean 0.94 1.08
  SD 0.25 0.20
vs. recovery group nS
Interval between commencement of PSL and that of CyA 
(days)
  Mean 32.0 29.4
  SD 39.3 18.5
  vs. recovery group nS
Clinical symptoms
  Dyspnea
    number 9 5
    vs. recovery group nS
  non-productive cough
    number 9 6
    vs. recovery group nS
Laboratory findings
  KL-6 (U/L)
    Mean 1055 1865
    SD 625 2220
    vs. recovery group nS
  PaO2 in room air (mmhg)
    Mean 77.8 59.8
    SD 15.0 7.2
    vs. recovery group 0.017
  %VC (%)
    Mean 86.9 58.3
    SD 13.6 18.7
    vs. recovery group 0.013
  %DLco (%)
    Mean 57.4 42.1
    SD 9.01 11.9
    vs. recovery group nS
  Total CT score
    Mean 8.21 16.7
    SD 5.55. 6.12
    vs. recovery group 0.013
Other treatment
  Methylprednisolone pulse
    number 3 6
(Continued)
Table 2. (Continued)
Recovery 
group
Death 
group
  IVIg
    number 0 5
  Pe
    number 0 2
  IVCY
    number 0 3
Abbreviations: CyA, cyclosporin A; DLco, diffusing capacity for carbon 
monoxide;  DM,  dermatomyositis;  IVCY,  cyclophosphamide  pulse; 
IVIg,  high-dose  intravenous  immunoglobulin;  NS,  not  significant;  PE, 
plasma exchange; PSL, prednisolone; SD, standard deviation; VC, vital 
capacity.Shimojima et al
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Table 3. Clinical profiles of patients treated with continuous intravenous administration of CyA.
patient Age/sex Diagnosis clinical symptoms Respiratory function tests Total cT  
score  
on starting  
intravenous  
cyA
Methyl  
psL  
pulse  
therapy
psL cyA Other  
treatments
Adverse  
effects
Therapeutic   
outcome Dyspnea cough paO2 in  
room air
%Vc %DLco Interval from  
admission to  
commencement  
of cyA (days)
Duration of oral cyA  
before intravenous  
administration  
(days)
Duration of  
continuous  
intravenous  
administration  
of cyA (days)
Oral cyA after  
intravenous  
administration
1 65/F DM + + 62.8 nD nD 19 + + 7 0 15 − Pe, IVIg renal  
dysfunction  
eruptions
Death
2 55/F CADM + + 68.0 45.0 nD 16 + + 39 5 14 − IVCY, IVIg − Death
3 56/M CADM + + 61.8 43.6 nD 22 + + 0 4 15 − Pe, IVIg − Death
4 54/F DM + + 50.8 nD nD 24 + + 0 0 10 − IVCY, IVIg renal  
dysfunction
Death
5 52/F DM + + 60.6 45.5 31.5 16 + + 0 0 7 + − − recovery
6 57/M DM + + 61.2 61.4 63.6 14 + + 0 0 15 + − − recovery
Abbreviations: CADM, clinically amyopathic dermatomyositis; CyA, cyclosprin; DLco, diffusing capacity for carbon monoxide; DM, dermatomyositis; 
IVCY, intravenous cyclophosphamide; IVIg, intravenous high-dose immunoglobulin; nD, not done; Pe, plasma exchange; PSL, prednisolone; VC, vital 
capacity.
therapy  and  other  intensive  immunomodulatory 
treatment,  such  as  plasma  exchange  and  high-
dose  intravenous  cyclophosphamide.  Three  of  the 
6 patients had CADM. The total CT scores of each 
patient before and after starting coadministration of 
PSL and CyA are shown in Figure 1. All DM patients 
in the recovery group showed decreases or at least 
no increase in the total CT score from 1 month after 
starting  coadministration  of  PSL  and  CyA.  There 
were significant decreases in the total CT scores 1, 3, 6 
and 12 months after starting coadministration of PSL 
and CyA compared with before (P , 0.05). All DM 
patients in the death group showed increases in the 
total CT score suggestive of worsening of IP even 
after starting coadministration of PSL and CyA, and 
died within approximately 3 months after admission. 
In PM 2 patients received PSL and CyA, and both 
recovered  from  active  IP  without  serious  adverse 
events, although the total CT score in 1 remained 
at a slightly high level owing to inactive interstitial 
sequellae  12  months  after  starting  this  treatment. 
No  patients  receiving  PSL  alone  showed  any  life-
threatening complications.
To investigate clinical indices predicting therapeutic 
outcomes in IP complicating PM/DM, we compared 
clinical symptoms and laboratory data on adding CyA in 
the death group with those of the recovery one (Table 2). 
PaO2 in room air and %VC were significantly lower in 
the death group than in the recovery one (P , 0.05). 
The  death  group  showed  lower  %  DLco  compared 
with  the  recovery  one,  but  no  statistical  difference 
was  present.  The  total  CT  score  was  significantly 
higher in the death group than in the recovery one 
(P  ,  0.05). There  was  no  significant  difference  in 
clinical  symptoms,  such  as  non-productive  cough 
and dyspnea, KL-6, initial dose of PSL or the interval 
from commencement of PSL to that of CyA between 
the death and recovery groups. Other treatments, such 
as  methyprednisolone  pulse  therapy  and  high-dose 
intravenous  immunoglobulin,  were  more  frequently 
performed in the death group than in the recovery one 
in order to avoid worsening of respiratory failure.
Continuous intravenous  
administration of CyA
Continuous  intravenous  administration  of  CyA 
was performed in 6 DM patients, including 2 with 
CADM. Clinical profiles and therapeutic outcomes 
of  these  patients  are  summarized  in  Table  3.  All 
of the patients required oxygen therapy on or after 
admission  because  of  severe  dyspnea  and  non-
productive cough with low levels of PaO2 in room 
air, %VC and %DLco, although respiratory function 
tests could not be performed in some of them. The 
duration of continuous intravenous administration of 
CyA was 7 to 15 days (mean 12.5 ± 3.3 days), and 
the interval between admission to our hospital and 
commencement of this treatment was 0 to 44 days CyA and PSL in acute IP complicating PM/DM
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Table 3. Clinical profiles of patients treated with continuous intravenous administration of CyA.
patient Age/sex Diagnosis clinical symptoms Respiratory function tests Total cT  
score  
on starting  
intravenous  
cyA
Methyl  
psL  
pulse  
therapy
psL cyA Other  
treatments
Adverse  
effects
Therapeutic   
outcome Dyspnea cough paO2 in  
room air
%Vc %DLco Interval from  
admission to  
commencement  
of cyA (days)
Duration of oral cyA  
before intravenous  
administration  
(days)
Duration of  
continuous  
intravenous  
administration  
of cyA (days)
Oral cyA after  
intravenous  
administration
1 65/F DM + + 62.8 nD nD 19 + + 7 0 15 − Pe, IVIg renal  
dysfunction  
eruptions
Death
2 55/F CADM + + 68.0 45.0 nD 16 + + 39 5 14 − IVCY, IVIg − Death
3 56/M CADM + + 61.8 43.6 nD 22 + + 0 4 15 − Pe, IVIg − Death
4 54/F DM + + 50.8 nD nD 24 + + 0 0 10 − IVCY, IVIg renal  
dysfunction
Death
5 52/F DM + + 60.6 45.5 31.5 16 + + 0 0 7 + − − recovery
6 57/M DM + + 61.2 61.4 63.6 14 + + 0 0 15 + − − recovery
Abbreviations: CADM, clinically amyopathic dermatomyositis; CyA, cyclosprin; DLco, diffusing capacity for carbon monoxide; DM, dermatomyositis; 
IVCY, intravenous cyclophosphamide; IVIg, intravenous high-dose immunoglobulin; nD, not done; Pe, plasma exchange; PSL, prednisolone; VC, vital 
capacity.
(mean  9.2  ±  17.3  days).  Three  patients  started  to 
receive  continuous  intravenous  administration  of 
CyA right after admission to our hospital because of 
rapidly progressive respiratory failure, and of these 2 
(patients 5 and 6) completely recovered from IP. After 
reaching stable general status the administration route 
of CyA was changed from intravenous to oral in both 
patients. As a representative case the clinical course 
of patient 6 is shown in Figure 2. IP quickly improved 
in parallel with a decrease in serum CK and an increase 
in SaO2 after starting continuous intravenous infusion 
of  CyA  and  methylprednisolone  pulse  therapy 
followed by PSL. The administration route of CyA 
was successfully changed from intravenous to oral 2 
weeks after admission. Nevertheless, the remaining 
1 (patient 4), who had already shown consciousness 
disturbance  due  to  hypoxia  on  admission,  showed 
improvement of IP only when the blood concentration 
of CyA was raised to 450 ng/mL or higher. Renal 
dysfunction ascribable to CyA quickly worsened, and 
the patient died of respiratory failure during tapering 
continuous intravenous infusion of this drug.
Discussion
In the present study we reviewed the clinical profiles of 
PM/DM patients who had received coadministration of 
CyA and PSL in order to treat associated active IP. All of 
the patients receiving PSL + CyA, therefore, had active 
IP, while those receiving PSL alone did not. Considering 
that the PSL + CyA group showed a significantly higher 
frequency of ulcerative skin lesions and arthralgia than 
PSL alone before treatment, DM associated with active 
IP may have a systemic inflammatory process affecting 
visceral organs, such as vasculitis, in the background, 
as shown in the previous report.16 A significantly higher 
level of CRP in PSL + CyA than in PSL alone also sup-
ports the possible presence of systemic vasculitis in 
DM associated with active IP.
Oral administration of immunosuppressive agents, 
particularly  CyA,  is  often  employed  for  treatment 
of acute IP complicating DM in addition to PSL and 
methylprednisolone pulse therapy.9,17–19 In the present 
study 15 DM patients in the recovery group showed 
quick decreases or at least no increase in the total CT 
score after starting coadministration of CyA and PSL. 
Nevertheless, oral CyA has been reported to some-
times  fail  to  sufficiently  avoid  deterioration  of  IP, 
resulting in unfavorable outcomes even if this drug is 
started from the early phase of illness.20 In the pres-
ent study 6 DM patients died of respiratory failure 
due to acute IP despite administration of oral CyA. 
Among them 4 patients showed an evident delay in 
commencement of CyA, but in the remaining 2 both 
PSL and oral CyA were started almost simultaneously 
right after admission to our hospital in good general 
status with relatively low values of the total CT score. 
One possible cause of the unfavorable outcome is that 
IP was rapidly progressive. In other words, IP may Shimojima et al
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Figure 2. The clinical course of patient 6, showing a decrease in CK and an increase in SaO2 during continuous intravenous infusion of CyA and methylpred-
nisolone pulse therapy followed by PSL. The administration route of CyA was successfully changed from intravenous to oral 2 weeks after admission. 
Abbreviations: CK, creatine kinase; CT, computed tomography; CyA, cyclosporin A; IV, intravenous; PSL, prednisolone; SaO2, arterial oxygen saturation.
have become irreversible and extensive before CyA 
extended immunosuppressive action. The other pos-
sible cause is that blood concentrations of CyA were 
not high enough to suppress the disease activity of IP. 
We raised the administration dose of oral CyA within 
several days after commencement in these 2 patients 
in order to keep the trough concentration between 100 
and 150 ng/mL, but IP quickly worsened during this 
period. Oral CyA suppresses autoreactive T cells in 
conjunction with an increase in blood concentrations 
after  absorption  from  the  gastrointestinal  tract. As 
many exogenous factors, such as food and drugs, can 
affect the therapeutic efficacy of oral CyA by readily 
modifying its absorption and metabolism, continu-
ous intravenous administration is often employed for 
treatment of rejection in organ transplantation21,22 and 
inflammatory bowel disorders, including ulcerative 
colitis.23,24 In the present study 6 DM patients with 
active IP received continuous intravenous administra-
tion of CyA because of respiratory failure requiring 
oxygen  therapy  with  or  without  mechanical  venti-
latory support. Four patients showed extensive and 
probably irreversible damage in both lungs at com-
mencement of the continuous intravenous adminis-
tration of CyA, finally resulting in death, while the 
remaining 2 received this treatment from admission 
to our hospital, and quickly recovered from IP. These 
results suggest that the continuous intravenous admin-
istration of CyA may be a potent therapeutic option in 
IP complicating DM, particularly in the early phase CyA and PSL in acute IP complicating PM/DM
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of  illness,  with  regard  to  its  capability  of  quickly 
elevating the blood concentration and stabilizing it.
With continuous intravenous administration of CyA 
both therapeutic effects and adverse events, such as 
renal dysfunction, depend on its blood concentration. 
For  therapeutic  efficacy  the  appropriate  blood  con-
centration  with  continuous  intravenous  infusion  has 
been  reported  to  be  approximately  2.55-times  as 
high  as  the  trough  level  with  oral  administration.22 
  Considering that the appropriate trough level of CyA in 
the oral administration is 80–150 ng/mL, therefore, the 
blood concentration should be kept at approximately 
200–380 ng/mL in continuous intravenous infusion. 
In the present study we controlled the administration 
speed of CyA in order to keep the blood concentration 
at 250–350 ng/mL. In the term of safety, adverse events 
ascribed to CyA have been reported to be dependent on 
the length of continuous intravenous administration but 
not on the blood concentration at 300–500 ng/mL.23,25,26 
To reduce the possibility of adverse events, therefore, 
we need to switch the continuous intravenous infusion 
of CyA to oral administration as soon as possible after 
reaching  stable  general  status.  In  the  present  study 
2 patients showed successful transition from continuous 
intravenous infusion of CyA to oral administration in 
at most 2 weeks. Renal dysfunction with or without 
skin eruptions occurred in 2 patients, and of these it 
rapidly worsened in 1 because the blood concentration 
of CyA had to be maintained at 450 ng/mL or higher 
for 10 days in order to treat IP.
According to several recent reports the presence 
of autoantibodies to CADM-140 in serum and hyper-
ferritinemia are strongly relevant to poor prognosis 
in IP complicating PM/DM.27,28 At the present time, 
however, the anti-CADM-140 antibody remains com-
mercially unavailable. To discover other clinical factors 
suggestive of poor prognosis, we investigated whether 
or not there was a difference in laboratory data, respi-
ratory function and the total CT score between the 
death and recovery groups of DM associated with IP. 
No significant difference was seen in laboratory data, 
including KL-6, but PaO2 and %VC were significantly 
lower and the total CT score was significantly higher in 
the death group than in the recovery one. Respiratory 
function tests showed a lower level also in %DLco 
in the death group than in the recovery one, although 
there was no statistical difference. These results sug-
gest that respiratory function, such as PaO2, %VC and 
%DLco, may be useful as clinical indices predicting a 
poor prognosis. The continuous intravenous adminis-
tration of CyA is probably adequate for DM patients 
with active IP who show malfunction in respiratory 
function tests from the early phase of illness.
In conclusion, coadministration of oral CyA with 
PSL  is  effective  for  IP  complicating  PM/DM,  but 
its efficacy is sometimes insufficient, particularly in 
rapidly progressive cases. To more consistently and 
quickly suppress the disease activity of IP, the con-
tinuous intravenous administration of CyA might be 
a potent therapeutic option. Further prospective study 
of a larger set of patients is necessary in order to clar-
ify the clinical usefulness of this treatment.
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